UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug

BioMarin To Re-Engage With Process But Is Doubtful Of Outcome

A decision by England’s High Court to reject claims that HTA body NICE acted unlawfully when evaluating BioMarin’s PKU treatment has quashed hopes that NICE’s Highly Specialized Technologies program will become more widely used to evaluate rare disease treatments. Lawyers representing a PKU patient are planning to appeal the judgement.

Gavel
High Court Judge Rejects Claims NICE Acted Unlawfully

A high court judge in England has rejected an application for a judicial review of the way that the health technology appraisal body NICE approached its evaluation of BioMarin’s Kuvan (sapropterin) for the rare metabolic disease phenylketonuria (PKU).

The decision has disappointed critics of NICE’s approach to rare disease treatments, including BioMarin, but the institute said the decision...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography